Clinical Study
Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular Carcinoma: Results of a Phase II Study
Table 3
Number of patients with treatment-related toxicity in the safety population ().
| | Toxicity (NCI-CTCAE), no. (%) | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Any |
| | Neutropenia | 5 (12.5%) | 10 (25%) | 15 (37.5%) | 1 (2.5%) | 31 (77.5%) | | Thrombocytopenia | 4 (10%) | 15 (37.5%) | 6 (15%) | 1 (2.5%) | 26 (65%) | | Anemia | 13 (32.5%) | 15 (37.5%) | 10 (25%) | 0 | 38 (95%) | | Alopecia | 6 (15%) | 1 (2.5%) | 0 | 0 | 7 (17.5%) | | Diarrhea | 10 (25%) | 10 (25%) | 0 | 0 | 20 (50%) | | Nausea/vomiting | 15 (37.5%) | 5 (12.5%) | 1 (2.5%) | 0 | 21 (52.5%) | | Neurotoxicity | 14 (35%) | 2 (5%) | 8 (20%) | 0 | 24 (60%) | | Nephrotoxicity | 10 (25%) | 4 (10%) | 6 (15%) | 0 | 20 (50%) | | Hepatotoxicity | 10 (25%) | 5 (12.5%) | 6 (15%) | 0 | 21 (52.5%) |
|
|
NCI-CTCAE indicates National Cancer Institute Common Terminology Criteria for Adverse Events.
|
